Related Experiment Video
Updated: Aug 4, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
Neuroleptic malignant syndrome associated with olanzapine
G A Filice1, B C McDougall, N Ercan-Fang
1Infectious Disease Section, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA.
Objective:
To report a case of neuroleptic malignant syndrome (NMS) associated with the use of olanzapine.
Case Summary:
A 67-year-old white man with bipolar disorder developed nausea and vomiting. After 12 days, he became confused, delirious, and manic. His only medications were olanzapine 10 mg/d and divalproex sodium 500 mg bid. He was admitted to a hospital and treated for dehydration and mania. Olanzapine was given on 6 of the first 7 hospital days. On hospital day 6, typical NMS developed with the body temperature increasing to 39.9 degrees C, obtundation, rigidity, tremor, diaphoresis, fluctuating pupillary diameter, labile tachycardia and hypertension, hypernatremia, and elevated serum creatine kinase. Olanzapine was stopped after hospital day 7, and the syndrome resolved by hospital day 12.
Discussion:
The patient had all of the major manifestations of NMS. There was no other likely explanation for his illness and he received no other drug likely to be associated with the syndrome. This is the first case reported in which NMS was associated with olanzapine.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Antipsychotic Drugs: Typical and Atypical Agents
Mania and Antimanic Drugs: Overview
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...

